Treatment of bone disorders in liver disease

Journal of Hepatology

Volumn 45, Issue 3, 2006, Pages 445-453

  Parés, Albert ^a   Guañabens, Núria ^a  

^a Digestive Diseases Unit   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CORTICOSTEROID; CYCLOSPORIN; ESTRADIOL; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MEDROXYPROGESTERONE ACETATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; RALOXIFENE; RIBAVIRIN; TESTOSTERONE; VITAMIN D; VITAMIN D DERIVATIVE; ZOLEDRONIC ACID;

BILIARY CIRRHOSIS; BONE ATROPHY; BONE DENSITOMETRY; BONE DENSITY; BONE DISEASE; BREAST TENDERNESS; CHOLESTASIS; CHRONIC HEPATITIS; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INDUCED CANCER; DRUG MEGADOSE; ESOPHAGITIS; FRACTURE; FRAGILITY FRACTURE; HEMOCHROMATOSIS; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOCALCEMIA; HYPOGONADISM; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; LIVER TRANSPLANTATION; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PHLEBOTOMY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SEX RATIO; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

BONE RESORPTION; FRACTURES, BONE; HUMANS; LIVER DISEASES; OSTEOPOROSIS; PREVALENCE; RISK FACTORS;

EID: 33746661618     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.06.007     Document Type: Review

References (91)

1. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest 115 (2005) 3318-3325
2. Report of WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, World Health Organ Tech Rep Ser 1994;843:1-129.
3. Stellon A.J., Davies A., Compston J., and Williams R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 89 (1985) 1078-1083
4. Mitchison H.C., Malcolm A.J., Bassendine M.F., and James O.F. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 94 (1988) 463-470
5. Diamond T., Stiel D., Lunzer M., Wilkinson M., Roche J., and Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 31 (1990) 82-87
6. Bonkovsky H.L., Hawkins M., Steinberg K., Hersh T., Galambos J.T., Henderson J.M., et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 12 (1990) 273-280
7. Hay J.E., Lindor K.D., Wiesner R.H., Dickson E.R., Krom R.A., and LaRusso N.F. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 14 (1991) 257-261
8. Guañabens N., Parés A., Navasa M., Martínez de Osaba M.J., Hernández M.E., Muñoz J., et al. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol 21 (1994) 24-28
9. Lindor K.D., Janes C.H., Crippin J.S., and Jorgensen Ram Dickson E.R. Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?. Hepatology 21 (1995) 389-392
10. Chen C.C., Wang S.S., Jeng F.S., and Lee S.D. Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis?. J Gastroenterol Hepatol 11 (1996) 417-421
11. Sinigaglia L., Fargion S., Fracanzani A.L., Binelli L., Battafarano N., Varenna M., et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 24 (1997) 1809-1813
12. Angulo P., Therneau T.M., Jorgensen A., DeSotel C.K., Egan K.S., Dickson E.R., et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 29 (1998) 729-735
13. Gallego-Rojo F.J., Gonzalez-Calvin J.L., Munoz-Torres M., Mundi J.L., Fernandez-Perez R., and Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28 (1998) 695-699
14. Bagur A., Mautalen C., Findor J., Sorda J., and Somoza J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif Tissue Int 63 (1998) 385-390
15. Pereira S.P., Bray G.P., Pitt P.I., Li F.M., Moniz C., and Williams R. Noninvasive assessment of bone density in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 11 (1999) 323-328
16. Ormarsdottir S., Ljunggren O., Mallmin H., Brahm H., and Loof L. Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol 31 (1999) 84-90
17. Corazza G.R., Trevisani F., Di Stefano M., De Notariis S., Veneto G., Cecchetti L., et al. Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci 45 (2000) 1392-1399
18. Springer J.E., Cole D.E., Rubin L.A., Cauch-Dudek K., Harewood L., Evrovski J., et al. Vitamin-D receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 118 (2000) 145-151
19. Parés A., Guañabens N., Alvarez L., De Osaba M.J., Oriola J., Pons F., et al. Collagen type Iα1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 33 (2001) 554-560
20. Menon K.V.N., Angulo P., Weston S., Dickson E.R., and Lindor K.D. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35 (2001) 316-323
21. Guañabens N., Parés A., Ros I., Caballería J., Pons F., Vidal S., et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 42 (2005) 573-577
22. Newton J., Francis R., Prince M., James O., Bassendine M., Rawlings D., et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 49 (2001) 282-287
23. Eastell R., Dickson E.R., Hodgson S.F., Wiesner R.H., Porayko M.K., Wahner H.W., et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 14 (1991) 296-300
24. Guañabens N., Parés A., Mariñoso L., Brancós M.A., Piera C., Serrano S., et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 85 (1990) 1356-1362
25. Kalef-Ezra J.A., Merkouropoulos M.H., Challa A., Hatzikonstantinou J., Karantanas A.H., and Tsianos E.V. Amount and composition of bone minerals in chronic liver disease. Dig Dis Sci 41 (1996) 1008-1013
26. Olsson R., Johansson C., Lindstedt G., and Mellstrom D. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol 29 (1994) 753-756
27. Lindor K.D., Jorgensen R.A., Tiegs R.D., Khosla S., and Dickson E.R. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 33 (2000) 878-882
28. Valero M.A., Loinaz C., Larrodera L., Leon M., Moreno E., and Hawkins F. Calcitonin and bisphosphonate treatment in bone loss after liver transplantation. Calcif Tissue Int 57 (1995) 15-19
29. Monegal A., Navasa M., Guañabens N., Peris P., Pons F., Martinez de Osaba M.J., et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60 (1997) 148-154
30. Floreani A., Fries W., Luisetto G., Burra P., Fagiuoli S., Boccagni P., et al. Bone metabolism in orthotopic liver transplantation: a prospective study. Liver Transpl Surg 4 (1998) 311-319
31. Crosbie O.M., Freaney R., McKenna M.J., Curry M.P., and Hegarty J.E. Predicting bone loss following orthotopic liver transplantation. Gut 44 (1999) 430-434
32. Hussaini S.H., Oldroyd B., Stewart S.P., Roman F., Smith M.A., Pollard S., et al. Regional bone mineral density after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 11 (1999) 157-163
33. Giannini S., Nobile M., Ciuffreda M., Iemmolo R.M., Dale Carbonare L., Minicuci N., et al. Long-term persistence of low bone density in orthotopic liver transplantation. Osteoporos Int 11 (2000) 417-424
34. Ninkovic M., Skingle S.J., Bearcroft P.W.P., Bishop N., Alexander G.J.M., and Compston J.E. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 12 (2000) 931-935
35. Isoniemi H., Appelberg J., Nilsson C.G., Makela P., Risteli J., and Hockerstedt K. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol 34 (2001) 299-305
36. Leidig-Bruckner G., Hosch S., Dodidou P., Ritschel D., Conradt C., Klose C., et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 357 (2001) 342-347
37. Trautwein C., Possienke M., Schlitt H.J., Boker K.H.W., Horn R., Raab R., et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 95 (2000) 2343-2351
38. Feller R.B., McDonald J.A., Sherbon K.J., and McCaughan G.W. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 5 (1999) 407-413
39. Meys E., Fontanges E., Fourcade N., Thomasson A., Pouyet M., and Delmas P.D. Bone loss after orthotopic liver transplantation. Am J Med 97 (1994) 445-450
40. Porayko M.K., Weisner R.H., Hay J.E., Krom R.A.F., Dickson E.R., Beaver S., et al. Bone disease in liver transplant recipients: incidence, timing and risk factors. Transplant Proc 23 (1991) 1462-1465
41. Hay J.E., Malinchoc M., and Dickson E.R. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 34 (2001) 292-298
42. Hamburg S.M., Piers D.A., Van den Berg A.P., Slooff M.J.H., and Haagsma E.B. Bone mineral density in the long term after liver transplantation. Osteoporos Int 11 (2000) 600-606
43. Monegal A., Navasa M., Guañabens N., Peris P., Pons F., Martinez de Osaba M.J., et al. Bone disease after liver transplantation. A long-term prospective study of bone mass changes, hormonal disorders and histomorphometric characteristics. Osteoporos Int 12 (2001) 484-492
44. Arnold J.C., Hauser D., Ziegler R., Kommerell B., Otto G., Theilmann L., et al. Bone disease after liver transplantation. Transplant Proc 24 (1992) 2709-2710
45. McDonald J.A., Dunstan C.R., Dilworth P., Sherbon K., Sheil A.G.R., Evans R.A., and Wüster C. Bone loss after liver transplantation. Hepatology 14 (1991) 613-619
46. Navasa M., Monegal A., Guañabens N., Peris P., Rimola A., and Muñoz-Gomez J. Bone fractures in liver transplant patients. Br J Rheumatol 33 (1994) 52-55
47. Navasa M., Forns X., Sanchez V., Andreu H., Marcos V., Borras J.M., et al. Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation. J Hepatol 25 (1996) 129-134
48. Riemens S.C., Oostdijk A., Van Doormaal J.J., Thijn C.J., Drent G., Piers D.A., et al. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. Osteoporos Int 6 (1996) 213-218
49. Reeves H.L., Francis R.M., Manas D.M., Hudson M., and Day C.P. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4 (1998) 404-409
50. Haagsma E.B., Thijn C.J.P., Post J.G., Slooff M.J.H., and Gips C.H. Bone disease after orthotopic liver tansplantation. J Hepatol 6 (1988) 94-100
51. Neuhaus R., Lohmann R., Platz K.P., Guckelberger O., Schon M., Lang M., et al. Treatment of osteoporosis after liver transplantation. Transplant Proc 27 (1995) 1226-1227
52. Rust C., Rau H., Gerbes A.L., Pape G.R., Haller M., Kramling H., et al. S Liver transplantation in primary biliary cirrhosis: risk assessment and 11-year follow-up. Digestion 62 (2000) 38-43
53. Sheiner P.A., Magliocca J.F., Bodian C.A., Kim-Schluger L., Altaca G., Guarrera J.V., et al. Long-term medical complications in patients surviving > or =5 years after liver transplant. Transplantation 69 (2000) 781-789
54. Compston J.E. Osteoporosis after liver transplantation. Liver Transpl 9 (2003) 321-330
55. Heaney R.P. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9 (1994) 1515-1523
56. McCaughan G.W., and Feller R.B. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 12 (1994) 223-231
57. Guañabens N., Parés A., Alvarez L., Martinez de Osaba M.J., Monegal A., Peris P., et al. Collagen related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 13 (1998) 731-738
58. Janes C.H., Dickson E.R., Okazaki R., Bonde S., McDonagh A.F., and Riggs B.L. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95 (1995) 2581-2586
59. Peris P., Parés A., Guañabens N., Del Río L., Pons F., Martínez de Osaba M.J., et al. Bone mass improves in alcoholics after two years of abstinence. J Bone Miner Res 9 (1994) 1607-1612
60. Cemborain A., Castilla-Cortazar I., Garcia M., Quiroga J., Muguerza B., Picardi A., et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 28 (1998) 122-131
61. Herlong H.F., Recker R.R., and Maddrey W.C. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 83 (1982) 103-108
62. Cuthbert J.A., Pak C.Y.C., Zerwekh J.E., Glass K.D., and Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 4 (1984) 1-8
63. Parés A., Guañabens N., Alvarez L., Monegal A., Caballería L., Ozalla D., et al. High osteoprotegerin and low RANKL levels in primary biliary cirrhosis. Relationship with the severity of liver disease but not with osteoporosis. Hepatology 40 (2004) 463A
64. Sambrook P., Birmingham J., Kempler S., Kelly P., Eberl S., Pocock N., et al. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5 (1990) 1211-1216
65. Movsowitz C., Epstein S., Fallon M., Ismail F., and Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 123 (1988) 2571-2577
66. Cverkovic M., Mann G.N., Romero D.F., Liang X.G., Ma T., Jee W.S.S., et al. The deleterious effects of long-term cyclosporine A, cyclosporine G and FK506 on bone mineral metabolism in vivo. Transplantation 57 (1994) 1231-1237
67. Solis-Herruzo J.A., Castellano G., Fernandez I., Muñoz R., and Hawkins F. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 33 (2000) 812-817
68. Trombetti A., Giostra E., Mentha G., Negro F., and Rizzoli R. Lack of evidence for ribavirin-induced bone loss. Hepatology 36 (2002) 255-257
69. AGA Technical Review on Osteoporosis in Hepatic Disorders. Gastroenterology 2003;125:941-66.
70. Goodman G.R., Dissanayake I.R., Sodam B.B., Gorodetsky E., Lu J., Ma Y.F., et al. Immunosuppressant use without bone loss-implications for bone loss after transplantation. J Bone Miner Res 16 (2001) 72-78
71. Neuhaus R., Kubo A., Lohmann R., Rayes N., Hierholzer J., and Neuhaus P. Calcitriol in prevention and therapy of osteoporosis after liver transplantation. Transplant Proc 31 (1999) 472-473
72. Dequeker J., Borghs H., Van Cleemput J., Nevens F., Verleden G., and Nijs J. Transplantation osteoporosis and corticoid-induced osteoporosis in autoimmune diseases: experience with alfacalcidol. Z Rheumatol 59 Suppl 1 (2000) 53-57
73. Crippin J.S., Jorgensen R.A., Dickson E.R., and Lindor K.D. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 89 (1994) 47-50
74. Olsson R., Mattsson L.-A., Obrant K., and Mellstrom D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 19 (1999) 188-192
75. Pereira S.P., O'Donohue J., Moniz C., Phillips M.G., Abraham H., Buxton M., et al. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther 19 (2004) 563-570
76. Ormarsdottir S., Mallmin H., Naessen T., Petren-Mallmin M., Broome U., Hultcrantz R., et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med. 256 (2004) 63-69
77. Diamond T.H., Stiel D., and Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 6 (1991) 39-43
78. Guañabens N., Parés A., Del Río L., Roca M., Gómez R., Muñoz J., et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 15 (1992) 345-349
79. Guañabens N., Parés A., Monegal A., Peris P., Pons F., Alvarez L., et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 113 (1997) 219-224
80. Floreani A., Chiaramonte M., Giannini S., Malvasi L., Lodetti M.G., Castrignano R., et al. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. J Hepatol 12 (1991) 217-223
81. Floreani A., Zappala F., Fries W., Naccarato R., Plebani M., D'Angelo A., et al. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 24 (1997) 239-244
82. Camisasca M., Crosignani A., Battezzati P.M., Albisetti W., Grandinetti G., Pietrogrande, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 20 (1994) 633-637
83. Wolfhagen F.H., Van Buuren H.R., Den Ouden J.W., Hop W.C., Van Leeuwen J.P., Schalm S.W., et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled trial. J Hepatol 26 (1997) 325-330
84. Guañabens N., Parés A., Ros I., Alvarez L., Pons F., Caballería L., et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 98 (2003) 2268-2274
85. Zein C., Jorgensen R., Clarke B., Wenger D., Keach J., Angulo P., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomised placebo-controlled trial. Hepatology 42 (2005) 761-762
86. Guañabens N., Vazquez I., Alvarez L., Pons F., Caballería L., Cerda D., et al. Alendronate 70 mg once-weekly is more effective and has a better tolerability than alendronate 10 mg daily in the treatment of osteopenia associated with primary biliary cirrhosis. J Bone Miner Res 20 (2005) S279
87. Ninkovic M., Love S., Tom B.D.M., Bearcroft P.W.P., Alexander G.J.M., and Compston J.E. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37 (2002) 93-100
88. Dodidou P., Bruckner T., Hosch S., Haas M., Klar E., Sauer P., et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 14 (2003) 82-89
89. Monegal A., Navasa M., Suárez M., Suárez-López S., García-González F., Serrano T., et al. Effects of intravenous pamidronate on bone loss after liver transplantation. Calcif Tissue Int 78 (2006) S148
90. Crawford B.A., Kam C., Pavlovic J., Byth K., Handelsman D.J., Angus P.W., et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144 (2006) 239-248
91. Levy C., Harnois D.M., Angulo P., Jorgensen R., and Lindor K.D. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 25 (2005) 117-121